Drug intelligence / Profile preview

palmitoylethanolamide + polydatin

Development stage
Unknown
Lead developer
Epitech
Modality
Small Molecules
Administration
Oral
01

Overview

Palmitoylethanolamide + polydatin is a combination product comprised of palmitoylethanolamide (PEA), an endogenous fatty acid amide with anti-inflammatory and neuroprotective effects, and polydatin (PLD), a natural glucoside precursor to resveratrol. PEA modulates mast cell activation and inflammation, while polydatin provides antioxidant activity and inhibits vascular endothelial growth factor (VEGF) expression. The combination’s synergistic action results in reduced pain, inflammation, and oxidative stress, with demonstrated efficacy in conditions such as endometriosis-associated chronic pelvic pain, irritable bowel syndrome, and interstitial cystitis/bladder pain syndrome. Mechanistically, the combination acts via mast cell inhibition, antioxidant effects, and downregulation of proinflammatory cytokines and angiogenic factors. It is typically formulated as a micronized oral dietary supplement and is not classified as a pharmaceutical drug.

Brand names
Pelvilen Forte
Other names
m-PEA-PolPEA/PLD combinationco-micronized palmitoylethanolamide/polydatin
02

Targets

CB (Cannabinoid receptors)TRPV1 (Transient receptor potential cation channel subfamily V member 1)PPARA (Peroxisome proliferator-activated receptor alpha)

Beyond the preview

Go deeper on palmitoylethanolamide + polydatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on palmitoylethanolamide + polydatin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call